Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2002

View Archived Issues

Schering-Plough presents 2001 annual report

Potent inhibitors of angiogenesis derived from thrombospondin-1

Cephalon designs new inhibitors of VEGF-dependent angiogenesis with good oral antitumor activity

Preliminary phase I results for ILX-651 discussed at AACR meeting

Preclinical characterization of Ro-31-7453, a new cell cycle inhibitor

SAR leading to TBC-3711, a potent, orally active, ETA-selective endothelin antagonist

Enrollment completed in phase II/III trial of Neurodex for emotional lability

Novartis presents data on the balanced NK1/NK2 antagonist DNK-333

Phase IB safety study of Moli-1901 in cystic fibrosis yields favorable results

Health Canada approves phase I/II Reolysin trial in patients with recurrent malignant glioma

ChemGenex uses chemical genomics to advance experimental anticancer drugs

Affitech acquires exclusive worldwide license for Troybodies technology

GW expands phase III program for cannabis-based medicines

Phase I/II results for WX-G250 in metastatic RCC indicate clinical benefit and good tolerance

Alliance for research on interferon gamma-1b for asthma

HE-2200 for potentiating impaired immune systems

Inhibitors of Src tyrosine kinases reported by AstraZeneca

Pharmacodynamic and pharmacokinetic effects of renzapride examined in IBS

Collaboration to identify single-chain antibody therapeutics

FDA concerns will delay Ariza marketing

Calcium receptor antagonists especially useful in osteoporosis according to JT

Agouron designs new series with protein kinase-inhibitory and antitumor activity

Roche patents prodrugs of NMDA receptor antagonists

New MC4-selective agonists useful in obesity, etc.

Patent covers Genentech's new alpha4 integrin receptor ligands

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...